Skip to content
DataLookout
Menu

NCT07672574

Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words
    • Primary endpoints: details revised at 1 of 3 entries
    • Primary and study completion pushed from Sep 26, 2026 to Jan 31, 2027
    • Secondary endpoints: details revised at 3 of 10 entries
  2. Notable Recruitment opened
    • Start date: Jul 20, 2026 to Sep 9, 2026
    • Primary and study completion moved earlier from Dec 31, 2026 to Sep 26, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Absolute bioavailability of ontunisertib following oral and IV administration
Timeframe: Through study completion, an average of 8 days
Cumulative amount of total radioactivity excreted in urine and feces
Timeframe: Through study completion, an average of 10 days
Chemical structure of each metabolite accounting for ≥10% of circulating total radioactivity and Metabolite profiling accounting for >80% of total radioactivity recovered in urine and/or feces
Timeframe: Through study completion, an average of 10 days

Secondary (9)

PK parameter (AUClast)
Cumulative amount of total radioactivity excreted in urine and feces following IV administration
Whole blood-to-plasma concentration ratios for total radioactivity
Number of participants with adverse events (AEs)
Number of participants with abnormal physical examinations
Show 4 moreShow less
Number of participants with abnormal vital signs
Number of participants with abnormal ECGs parameters
Number of participants with abnormal clinical laboratory safety tests
Chemical structure analysis of metabolites accounting for ≥10%

Arms and interventions

OntunisertibExperimental

Participants will receive single oral dose of ontunisertib

[14C]ontunisertib solution for infusionExperimental

Participants will receive single IV dose of \[14C\]ontunisertib

[14C]ontunisertibExperimental

Participants will receive single oral dose of \[14C\]ontunisertib

Drugs: Ontunisertib, [14C]ontunisertib

Sites

1 site in 1 country

  • Quotient Sciences LimitedNottingham, United Kingdom